H.B. Fuller Company Dossier - Source-backed chat

H.B. Fuller Company

FULNYSE

SectorMaterials

IndustrySpecialty Chemicals

Beta (adjusted)0.98

Intrinsic Value $71.62median of 6 methods · middle span $64-$76based on filings through 30 May 2026

Market Price $50.23Price as of 1 Oct 2026

UndervaluedIntrinsic value is 43% above the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

Data confidence Sign in to view data confidence

Market Cap $2.7B

Enterprise Value $4.7B

Shares Outstanding 55.2M diluted

Moat Rating None

Last ex-dividend30 Jul 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

H.B. Fuller (FUL) is navigating a complex macroeconomic environment characterized by soft volume demand, geopolitical supply chain disruptions, and input cost inflation. While the company has successfully expanded its adjusted gross margins and consistently beaten EPS estimates through its restructuring program and strategic pricing initiatives, its top-line organic revenue continues to contract (down 1.3% in Q1 2026). The company's transition away from lower-margin segments toward high-value areas such as medical, aerospace, and electronics is promising, but persistent volume declines warrant a cautious Hold stance until organic volume recovery materializes.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets7 analysts · as of 18 Aug 2026

Low · most bearish analyst$67.00

Mean target$73.29

High · most bullish analyst$80.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$67.0015%

Input cost inflation escalates due to prolonged geopolitical conflicts in the Middle East, severely compressing gross margins. Volume declines worsen in core packaging and construction segments, and the exit from the solar adhesive business causes a larger-than-expected revenue drag, pushing the stock down toward its historical valuation floors.

Base CaseCentral scenario

$73.2960%

Matches the consensus mean

Organic revenue remains flat to slightly positive as targeted price increases offset moderate volume declines. The company successfully achieves its raised $15 million Quantum Leap cost savings target for FY 2026, maintaining adjusted EBITDA margins in the mid-15% range. Leverage gradually deleverages toward the 2.5x-3.0x target range.

Bull CaseUpside scenario

$80.0025%

Accelerated volume recovery in industrial and construction end markets, combined with faster-than-expected cost synergies from the Quantum Leap restructuring program, drives EBITDA margins toward the company's >20% target. High-margin segments like medical adhesives (growing at nearly 20% in Europe) and aerospace engineering adhesives scale rapidly, leading to significant multiple expansion.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Largest pureplay adhesives provider globally with a highly diversified product portfolio across 30+ market segments, reducing single-point-of-failure risk.
Strong pricing power and execution of self-help initiatives, such as the Quantum Leap program, which expanded adjusted gross margins by 170 bps year-over-year in Q1 2026.
Strategic pivot toward high-margin, high-growth secular accelerators including medical adhesives, aerospace, and advanced electronics.

Key Investment Risks

Persistent organic revenue decline (down 6.6% in Q1 2026) driven by lower volume, indicating weak underlying demand in core industrial and construction end markets.
High exposure to volatile raw material costs (constituting approximately 75% of cost of sales) and geopolitical supply chain disruptions.
Elevated leverage profile with net debt-to-adjusted EBITDA at 3.1x, limiting near-term capital allocation flexibility for M&A.

Thesis Invalidation Triggers

Adjusted gross margin falling below 30% due to unhedged raw material cost inflation.
Organic volume decline accelerating beyond high single digits in consecutive quarters.
Failure to deleverage net debt-to-adjusted EBITDA below 3.0x by the end of FY 2026.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.